Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Arnesen, T.; Thompson, P.R.; Varhaug, J.E.; Lillehaug, J.R.
    The protein acetyltransferase ARD1: a novel cancer drug target? (2008), Curr. Cancer Drug Targets, 8, 545-553.
    View publication on PubMed

Natural Substrates/ Products (Substrates)

EC Number Natural Substrates Organism Comment (Nat. Sub.) Natural Products Comment (Nat. Pro.) Rev. Reac.
2.3.1.255 acetyl-CoA + beta-catenin Homo sapiens
-
 ?
-
 ?

Organism

EC Number Organism UniProt Comment Textmining
2.3.1.255 Homo sapiens
-
-
-

Source Tissue

EC Number Source Tissue Comment Organism Textmining
2.3.1.255 lung cancer cell
-
 Homo sapiens
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
2.3.1.255 acetyl-CoA + beta-catenin
-
 Homo sapiens ?
-
 ?

Synonyms

EC Number Synonyms Comment Organism
2.3.1.255 ARD1
-
 Homo sapiens

General Information

EC Number General Information Comment Organism
2.3.1.255 malfunction knockdown of acetyltransferase ARD1 significantly reduces the growth rate of human cancer cell lines. Furthermore, ARD1 knockdown induces apoptosis or sensitizes cells to drug induced apoptosis. Enzyme knockdown reduces the transcriptional activity of the beta-Catenin/TCF4 complex, downregulating cyclin D1 and thereby promoting G1-arrest and inhibition of cell proliferation of lung cancer cells Homo sapiens
2.3.1.255 physiological function the enzyme acts in complex with the NATH protein and catalyzes cotranslational acetylation of protein N-termini Homo sapiens